Melanoma and Sarcoma Center - Clinical Trials

Specialty Cancer Centers

New Patient Appointment


Clinical Trials

  • Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab

    •OS rate, defined as the proportion of patients alive after 2 years of follow-up time [ Time Frame: 2 years ] [ Designated as safety issue: No ] Will be estimated and compared between the two arms using the Fisher's exact test based on two-sided overall type I error rate of 0.05 adjusting for two-interim analysis. Distribution will be estimated using the Kaplan-Meier method.

  • A Randomized Phase II Trial of Intermittent Versus Continuous Dos

    The primary objective of this study is to compare progression-free survival with intermittent dosing and continuous dosing of dabrafenib and trametinib among patients with metastatic BRAFV600E/K mutant melanoma.

  • EAP-Combination Yervoy and Opdivo

    The primary objective of this study is to provide treatment with nivolumab for the combination with ipilimumab (Yervoy) to subjects who are anti-CTLA-4 and anti-PD-1 treatment-naive and have unresectable or metastatic melanoma. Safety data will be collected and reported according to health authority regulations and BMS regulations. QoL data will be measured using the EORTC QLQ-C30. Additionally, survival data collection (up to 5 years following the subject¡¦s start of treatment with nivolumab) is recommended to be part of the subject¡¦s follow up and will be summarized or listed, depending on the extent of such collected data

  • A Phase 3, Study of Adjuvant Immunotherapy with Nivolumab

    To compare the efficacy, as measured by recurrence free survival (RFS), provided by nivolumab versus ipilimumab in subjects with completely resected Stage IIIb/c or Stage IV NED melanoma who are at high-risk for recurrence.

  • Melanoma Antigen Vaccine Immunotherapy Study

    The purpose of this study is to determine how safe and how well POL-103A works in preventing the relapse of melanoma after patients who have undergone surgery.